(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 December 2010 (23.12.2010)

PCT

(10) International Publication Number
WO 2010/146550 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *C07K 16/32* (2006.01)

(21) International Application Number:
PCT/IB2010/052711

(22) International Filing Date:
16 June 2010 (16.06.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/218,193 18 June 2009 (18.06.2009) US

(71) Applicants *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US). **RINAT NEUROSCIENCE CORPORATION** [US/US]; 230 East Grand Avenue, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HOSTOMSKY, Zdenek** [US/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US). **LI, Kang** [US/US]; 11376 Saddle Cove Lane, San Diego, CA 92130 (US). **LIPPINCOTT, John, Andrew** [US/US]; 12427 Via Cabezon, San Diego, CA 92129 (US). **PENG, Qinghai** [US/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US). **STONE, Donna, Marie** [US/US]; Rinat Neuroscience Corporation, 230 East Grand Avenue, South San Francisco, CA 94080 (US). **WEI, Ping** [US/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agent: **BENSON, Gregg C.**; Pfizer Inc., Eastern Point Road MS9114, Groton, CT 06340 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to the identity of the inventor (Rule 4.17(i))*

[Continued on next page]

(54) Title: ANTI NOTCH-1 ANTIBODIES

FIG. 1

PCR synthesis of N1-NRR-TM(-) cDNA



(57) Abstract: This invention is directed toward monoclonal antibodies that bind specifically to Notch1. In one embodiment, the antibodies binds to at least a first epitope and a second epitope, wherein the first epitope resides with the LinA domain of the Notch1 negative regulatory region (NRR), and the second epitope resides within the HD-C domain of the Notch1 NRR.

WO 2010/146550 A1

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*